Jonathan L Kaufman

33PUBLICATIONS
123CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsMedical biochemistry - inorganic elements and compounds
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Mar 16, 2025
BCL2 inhibition for multiple myeloma and AL amyloidosis.

Lorenzo Cani, Vikas A Gupta, Jonathan L Kaufman

|Dec 04, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.

Dan T Vogl, Shebli Atrash, Sarah A Holstein

|Sep 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta

|Jul 08, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

Ajai Chari, Jonathan L Kaufman, Jacob Laubach

|Apr 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman

Pageof 6

Frequent Collaborators

12 joint publications

Ajay Nooka

12 joint publications

Craig C Hofmeister

9 joint publications

Madhav V Dhodapkar

6 joint publications

Sagar Lonial